Heparin-induced thrombocytopenia cost-effectiveness of therapy: Difference between revisions
Gerald Chi- (talk | contribs) Created page with "__NOTOC__ {{Heparin-induced thrombocytopenia}} {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] ==Overview== ==Cost-E..." |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Heparin-induced thrombocytopenia}} | {{Heparin-induced thrombocytopenia}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu] | {{CMG}}; '''Associate Editor-In-Chief:''' {{CZ}}, Aric C. Hall, M.D., [mailto:achall@bidmc.harvard.edu], {{shyam}} | ||
==Overview== | ==Overview== | ||
| Line 7: | Line 7: | ||
==Cost-Effectiveness of Therapy== | ==Cost-Effectiveness of Therapy== | ||
The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors.<ref name="pmidPMID27793877">{{cite journal| author=Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y et al.| title=Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. | journal=Blood | year= 2016 | volume= 128 | issue= 26 | pages= 3043-3051 | pmid=PMID27793877 | doi=10.1182/blood-2016-07-728030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27793877 }} </ref> Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin. | |||
<ref name="pmidPMID27793877">{{cite journal| author=Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y et al.| title=Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States. | journal=Blood | year= 2016 | volume= 128 | issue= 26 | pages= 3043-3051 | pmid=PMID27793877 | doi=10.1182/blood-2016-07-728030 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27793877 }} </ref> | |||
==References== | ==References== | ||
Revision as of 02:07, 31 July 2017
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
FDA on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
CDC on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
Heparin-induced thrombocytopenia cost-effectiveness of therapy in the news |
|
Blogs on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]
Overview
Cost-Effectiveness of Therapy
The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors.[1] Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin. [1]
References
- ↑ 1.0 1.1 Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y; et al. (2016). "Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States". Blood. 128 (26): 3043–3051. doi:10.1182/blood-2016-07-728030. PMID PMID27793877 Check
|pmid=value (help).